share_log

石藥集團：石藥創新製藥股份有限公司截至2024年12月31日止年度之財務資料

CSPC PHARMA: FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2024

HKEX ·  Mar 20 13:33

Summary by Moomoo AI

石藥創新製藥於2025年3月20日發佈2024年度報告。報告期內，公司實現營業收入19.81億元人民幣，同比下降21.98%；歸屬於上市公司股東的淨利潤5,373萬元，同比下降87.63%；基本每股收益0.0384元。公司經營活動產生的現金流量淨額為-12.35億元，同比下降271.26%。截至2024年末，公司總資產60.22億元，較年初下降19.41%；歸屬於上市公司股東的淨資產37.31億元，較年初下降29.36%。報告期內，公司貨幣資金大幅減少，主要用於購買大額定期存單、股份回購及現金分紅；存貨增加主要由於新產品投產及咖啡因國外庫存增加；在建工程增加主要因巨石生物新廠房及辦公樓建設和保健食品及特醫食品生產項目建設。
石藥創新製藥於2025年3月20日發佈2024年度報告。報告期內，公司實現營業收入19.81億元人民幣，同比下降21.98%；歸屬於上市公司股東的淨利潤5,373萬元，同比下降87.63%；基本每股收益0.0384元。公司經營活動產生的現金流量淨額為-12.35億元，同比下降271.26%。截至2024年末，公司總資產60.22億元，較年初下降19.41%；歸屬於上市公司股東的淨資產37.31億元，較年初下降29.36%。報告期內，公司貨幣資金大幅減少，主要用於購買大額定期存單、股份回購及現金分紅；存貨增加主要由於新產品投產及咖啡因國外庫存增加；在建工程增加主要因巨石生物新廠房及辦公樓建設和保健食品及特醫食品生產項目建設。
Shijiazhuang Pharmaceutical Innovation Pharmaceutical Co., Ltd. published its 2024 annual report on March 20, 2025. During the reporting period, the company achieved revenue of 1.981 billion yuan, a year-on-year decrease of 21.98%; the net profit attributable to shareholders of the listed company was 53.73 million yuan, a year-on-year decrease of 87.63%; the basic EPS was 0.0384 yuan.The net cash flow from operating activities (CFO) of the company was -1.235 billion yuan, a year-on-year decrease of 271.26%. As of the end of 2024, the company had total Assets of 6.022 billion yuan, a decrease of 19.41% compared to the beginning of the year; the net Assets attributable to shareholders of the listed company was 3.731 billion yuan, a decrease of 29.36% compared to the beginning of the year.During...Show More
Shijiazhuang Pharmaceutical Innovation Pharmaceutical Co., Ltd. published its 2024 annual report on March 20, 2025. During the reporting period, the company achieved revenue of 1.981 billion yuan, a year-on-year decrease of 21.98%; the net profit attributable to shareholders of the listed company was 53.73 million yuan, a year-on-year decrease of 87.63%; the basic EPS was 0.0384 yuan.The net cash flow from operating activities (CFO) of the company was -1.235 billion yuan, a year-on-year decrease of 271.26%. As of the end of 2024, the company had total Assets of 6.022 billion yuan, a decrease of 19.41% compared to the beginning of the year; the net Assets attributable to shareholders of the listed company was 3.731 billion yuan, a decrease of 29.36% compared to the beginning of the year.During the reporting period, the company’s MMF decreased significantly, mainly used for purchasing large fixed-term deposits, share buybacks, and cash dividends; the inventory increased mainly due to the production of new products and increased foreign inventory of caffeine; the increase in construction projects was mainly due to the new factory and office building construction of Giant Stone Bio and the construction of health food and special medical food production projects.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 291

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
KINTOR PHARMA-B
09939
1.720
NT PHARMA
01011
0.255
REGENT PACIFIC
00575
0.465
KONTA CHINA
01312
0.028
PURAPHARM
01498
0.570
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Fed rate cut expectations for 2025 intensify. What’s your market outlook?
42%
58%
Bullish
Bearlish
1292 votes
FOMC Press Conference, March 19, 2025

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK